2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration

EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration - PDF(Abstract)

Pdf Summary

This study examined the clinical significance of chronic interstitial pneumonia induced by EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) administration in patients with non-small cell lung cancer (NSCLC). The researchers conducted a retrospective single-center cohort study of patients who received osimertinib or afatinib as a first-line treatment for advanced EGFR mutation-positive NSCLC. They evaluated chest computed tomography scans and clinical information during EGFR-TKI exposure and identified cases of chronic progression of interstitial pneumonia. The prevalence of chronic interstitial fibrosis was found to be 5% among the patients in this study. <br /><br />Among the five patients who exhibited chronic progression of interstitial pneumonia, the overall response rate to EGFR-TKI was 80%. One patient discontinued EGFR-TKI due to drug-related pneumonitis (DRP), and their pneumonic shadow improved after drug discontinuation. The pathological examination of this patient showed fibrosis and lymphocyte infiltration. The remaining four patients did not experience DRP. <br /><br />The study suggests that clinicians should be cautious of chronic interstitial pneumonia and carefully evaluate the risk of continuing EGFR-TKI treatment. This finding highlights the importance of monitoring patients receiving EGFR-TKI therapy for the development of interstitial pneumonia and the potential need to discontinue treatment if complications arise. Further research and evaluation are necessary to better understand the prevalence, disease course, and safety of EGFR-TKI continuation in patients with NSCLC.

Asset Subtitle

Yuki Sato

Meta Tag

Speaker Yuki Sato

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

chronic interstitial pneumonia

EGFR-TKI

non-small cell lung cancer

NSCLC

osimertinib

afatinib

chest computed tomography scans

clinical information

drug-related pneumonitis

fibrosis